Entera Bio (ENTX) Stock Price, News & Analysis

Company Overview

Entera Bio Ltd. is a clinical‐stage biotechnology company specializing in the development of orally administered peptide therapeutics. Leveraging a proprietary Intestinal Permeability Enhancement Technology (IPET), the company aims to transform peptide drugs—traditionally delivered by injection—into convenient once‐daily oral capsules. Headquartered in Rockville, Maryland, with research operations in Israel, Entera Bio focuses on addressing large‐market endocrinology and immunology indications by improving patient adherence and reducing healthcare costs associated with injectable therapies.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog designed to treat osteoporosis by stimulating bone formation. EB613 has completed multiple Phase 1 studies in healthy volunteers, demonstrating favorable safety and pharmacokinetic profiles. Entera Bio is also advancing EB612, another PTH‐based peptide tailored for hypoparathyroidism, with the goal of achieving stable regulation of calcium metabolism without the peaks and troughs seen with injections.

Beyond its endocrinology programs, Entera Bio is exploring the application of its IPET platform in immunology. A notable preclinical effort involves the oral delivery of cladribine, a small‐molecule immunomodulator currently used in the treatment of multiple sclerosis. This effort exemplifies the company’s strategic intent to expand its pipeline into additional therapeutic areas where improved oral bioavailability could enhance patient convenience and compliance.

Founded in 2006, Entera Bio is led by Ofer Spiegelman, President and Chief Executive Officer, whose background includes leadership roles at specialty pharmaceutical and biotechnology firms. The management team combines expertise in drug development, regulatory affairs and commercial strategy, supported by a board of directors with experience at leading global healthcare companies. As a Nasdaq‐listed entity (NASDAQ:ENTX), Entera Bio continues to build strategic partnerships and seek regulatory milestones to advance its oral peptide platform toward commercialization.

Key Stats

• Today's Range: $1.75 to $1.86
• 50-Day Range: $1.78 to $2.36
• 52-Week Range: $1.41 to $2.79
• Volume: 130,051 shs
• Average Volume: 67,499 shs
• Market Capitalization: $80.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Buy

Entera Bio Stock Analysis - MarketRank™

Entera Bio scored higher than 45% of companies evaluated by MarketBeat, and ranked 649th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Entera Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Entera Bio has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Entera Bio are expected to decrease in the coming year, from ($0.28) to ($0.55) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Entera Bio is -6.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Entera Bio is -6.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Entera Bio has a P/B Ratio of 7.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.18% of the float of Entera Bio has been sold short.

Short Interest Ratio / Days to Cover

Entera Bio has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Entera Bio has recently decreased by 9.47%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Entera Bio does not currently pay a dividend.

Dividend Growth

Entera Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.18% of the float of Entera Bio has been sold short.

Short Interest Ratio / Days to Cover

Entera Bio has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Entera Bio has recently decreased by 9.47%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Entera Bio this week, compared to 1 article on an average week.

Search Interest

1 people have searched for ENTX on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Entera Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.38% of the stock of Entera Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 14.11% of the stock of Entera Bio is held by institutions.

ENTX Stock Analysis - Frequently Asked Questions

How have ENTX shares performed this year?

Entera Bio's stock was trading at $2.12 at the start of the year. Since then, ENTX shares have decreased by 16.0% and is now trading at $1.78.

How were Entera Bio's earnings last quarter?

Entera Bio Ltd. (NASDAQ:ENTX) announced its quarterly earnings results on Friday, May, 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. The business earned $0.04 million during the quarter. Entera Bio had a negative trailing twelve-month return on equity of 95.10% and a negative net margin of 4,525.11%.

When did Entera Bio IPO?

Entera Bio (ENTX) raised $11 million in an IPO on Thursday, June 28th 2018. The company issued 1,400,000 shares at a price of $8.00 per share. Maxim Group served as the underwriter for the IPO and Joseph Gunnar was co-manager.

How do I buy shares of Entera Bio?

Shares of ENTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Entera Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Entera Bio investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY) and GE Aerospace (GE).

Company Calendar

• Last Earnings: 5/09/2025
• Today: 7/09/2025
• Next Earnings (Estimated): 8/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ENTX
• CIK: 1638097
• Web: www.enterabio.com
• Phone: (722) 532-7151
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Entera Bio: $10.00
• High Price Target: $10.00
• Low Price Target: $10.00
• Potential Upside/Downside: +461.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.26)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$9.54 million
• Net Margins: -4,525.11%
• Pretax Margin: -4,518.83%
• Return on Equity: -95.10%
• Return on Assets: -82.77%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.07
• Quick Ratio: 13.07

Sales & Book Value

• Annual Sales: $180 thousand
• Price / Sales: 449.45
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.23 per share
• Price / Book: 7.74

Miscellaneous

• Outstanding Shares: 45,450,000
• Free Float: 40,734,000
• Market Cap: $80.90 million
• Optionable: Optionable
• Beta: 1.46